US signs $1.95 billion deal with Pfizer, BioNTech for 100 million vaccine doses

Vial of a vaccine candidate

WASHINGTON: U.S. pharma giant Pfizer has signed a $ 1.95 billion deal with German biomtech as part of an aggression to launch the 100 million doses of the Chovid-19 vaccine early next year.

It is the largest transaction under Operation Warp Speed with the aim of accelerating the development, manufacture and distribution of corona virus vaccines, treatments and diagnostics.

Pfizer and Bio Ende, who are developing the drug, said in a statement that in the future, the American people will receive the vaccine for free, in line with the Trump administration’s commitment.

The U.S. government has issued preliminary orders under the agreement to provide 100 million doses if regulatory approval is obtained.

The U.S. government has the option of purchasing an additional 500 million doses from both companies.

Biotech and Pfizer have reduced their vaccine candidates to two frontrunners and are waiting for the green light to begin a mass trial with 30,000 healthy volunteers, which could happen later this month.

If the studies are successful, they hope to get some kind of emergency clearance by October 2020.

 

Earlier this month, they announced that their main candidate had produced more or less neutralizing antibodies in humans than those recovered in COVID-19 patients.

It is administered in very small doses, causing mild but temporary side effects that are considered normal.

“We are adding a portfolio of vaccines to increase the chance that at least one safe and effective vaccine will be available to the American people by the end of this year,” said Deal Health Secretary Alex Azar.

“We are proud to be a part of this effort to save Americans from this deadly virus,” said Albert Borley, chairman and CEO of Pfizer.

Vaccine Race

Labs around the world are trying to develop a vaccine to end a century of worst health crisis.

Already 200 dozen candidate vaccines have been developed during clinical trials with human volunteers.

Earlier this month, U.S. 6 signed a $ 1.6 billion deal for $ 100 billion.

In May, the government announced $ 1.2 billion for the Astrogenene candidate vaccine, developed in collaboration with Oxford University.

Johnson & Johnson announces US6456 million for vaccine candidate; Modena 6 486 million; 28 628 million for emergency biological solutions.

The government invests in production capacity at its own risk and spends crores of rupees on companies that make syringes, bottles and medical glass coated plastic containers.

RNA vaccine

The Pfizer-Biotech vaccine method is based on the use of messenger RNA, a genetic code derived from SARS-CoV-2, which penetrates into human cells to produce a synthetic form of the Wizer Spike protein.

It produces host antibodies. The concept behind the technology dates back decades, but the vaccine has never been regulated.

A biotech spokesman told AFP that two injections were needed for maximum protection with a booster shot seven days after the first injection.

It costs $ 39 to protect a person from a deadly virus, based on the price paid by the US government.

If the studies are successful, they hope to get some kind of emergency clearance by October 2020.

 

Earlier this month, they announced that their main candidate had produced more or less neutralizing antibodies in humans than those recovered in COVID-19 patients.

 

It is administered in very small doses, causing mild but temporary side effects that are considered normal.

 

“We are adding a portfolio of vaccines to increase the chance that at least one safe and effective vaccine will be available to the American people by the end of this year,” said Deal Health Secretary Alex Azar.

 

“We are proud to be a part of this effort to save Americans from this deadly virus,” said Albert Borley, chairman and CEO of Pfizer.

 

Vaccine Race

Labs around the world are trying to develop a vaccine to end a century of worst health crisis.

 

Already 200 dozen candidate vaccines have been developed during clinical trials with human volunteers.

 

Earlier this month, U.S. 6 signed a $ 1.6 billion deal for $ 100 billion.

 

In May, the government announced $ 1.2 billion for the Astrogenene candidate vaccine, developed in collaboration with Oxford University.

 

Johnson & Johnson announces US6456 million for vaccine candidate; Modena 6 486 million; 28 628 million for emergency biological solutions.

 

The government invests in production capacity at its own risk and spends crores of rupees on companies that make syringes, bottles and medical glass coated plastic containers.

 

RNA vaccine

The Pfizer-Biotech vaccine method is based on the use of messenger RNA, a genetic code derived from SARS-CoV-2, which penetrates into human cells to produce a synthetic form of the Wizer Spike protein.

 

It produces host antibodies. The concept behind the technology dates back decades, but the vaccine has never been regulated.

 

A biotech spokesman told AFP that two injections were needed for maximum protection with a booster shot seven days after the first injection.

 

It costs $ 39 to protect a person from a deadly virus, based on the price paid by the US government.

Leave a Reply

Your email address will not be published. Required fields are marked *